IRIS
TISEO, Marcello
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.775
AS - Asia 16.786
EU - Europa 9.927
SA - Sud America 2.732
AF - Africa 944
Continente sconosciuto - Info sul continente non disponibili 775
OC - Oceania 29
AN - Antartide 1
Totale 49.969
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.240
SG - Singapore 6.349
CN - Cina 3.499
IT - Italia 2.714
VN - Vietnam 2.675
BR - Brasile 2.040
IE - Irlanda 1.671
SE - Svezia 1.408
HK - Hong Kong 1.359
BD - Bangladesh 1.088
FR - Francia 720
DE - Germania 719
FI - Finlandia 625
ZA - Sudafrica 601
NL - Olanda 557
IN - India 395
GB - Regno Unito 322
RU - Federazione Russa 293
TR - Turchia 265
CA - Canada 253
AR - Argentina 251
AT - Austria 204
UA - Ucraina 155
ID - Indonesia 147
MX - Messico 143
IQ - Iraq 121
EC - Ecuador 115
JP - Giappone 115
PK - Pakistan 102
CO - Colombia 90
PL - Polonia 90
ES - Italia 87
PH - Filippine 87
CI - Costa d'Avorio 81
KR - Corea 78
CZ - Repubblica Ceca 75
BE - Belgio 74
VE - Venezuela 61
MA - Marocco 60
CL - Cile 57
UZ - Uzbekistan 53
SA - Arabia Saudita 46
PY - Paraguay 45
TH - Thailandia 44
KE - Kenya 42
TN - Tunisia 38
JO - Giordania 37
MY - Malesia 37
IR - Iran 34
TW - Taiwan 30
LT - Lituania 29
AZ - Azerbaigian 28
EG - Egitto 28
KZ - Kazakistan 25
PE - Perù 25
AU - Australia 24
ET - Etiopia 24
RO - Romania 24
JM - Giamaica 23
BO - Bolivia 22
AE - Emirati Arabi Uniti 20
UY - Uruguay 20
CR - Costa Rica 19
IL - Israele 19
GR - Grecia 18
HN - Honduras 18
NP - Nepal 18
BG - Bulgaria 15
LU - Lussemburgo 14
OM - Oman 14
CH - Svizzera 13
GT - Guatemala 13
PA - Panama 13
AL - Albania 12
BH - Bahrain 12
DZ - Algeria 12
PS - Palestinian Territory 12
SC - Seychelles 12
DO - Repubblica Dominicana 11
SN - Senegal 10
LB - Libano 9
SI - Slovenia 9
SV - El Salvador 9
SY - Repubblica araba siriana 9
TT - Trinidad e Tobago 9
BY - Bielorussia 8
GE - Georgia 8
NG - Nigeria 8
PT - Portogallo 8
RS - Serbia 8
BB - Barbados 7
DK - Danimarca 7
KG - Kirghizistan 7
QA - Qatar 7
BA - Bosnia-Erzegovina 6
HU - Ungheria 6
KH - Cambogia 6
KW - Kuwait 6
LV - Lettonia 6
MD - Moldavia 6
Totale 49.088
Salva come PNG Salva come JPEG
Città #
Singapore 3.318
Ashburn 2.246
San Jose 2.069
Chandler 1.715
Dublin 1.659
Dallas 1.330
Hong Kong 1.275
Santa Clara 1.135
Council Bluffs 949
Beijing 893
Ho Chi Minh City 839
Boardman 639
Hanoi 609
Johannesburg 551
New York 522
Parma 506
Los Angeles 446
Lauterbourg 412
Ann Arbor 363
Princeton 361
Shanghai 336
Milan 270
Munich 260
Dearborn 258
Nanjing 194
Des Moines 184
Helsinki 179
Buffalo 178
Wilmington 175
São Paulo 170
Chicago 168
Vienna 164
Moscow 163
Hefei 160
Columbus 155
Izmir 142
Rome 136
Bologna 135
Jacksonville 135
Da Nang 124
Seattle 117
Haiphong 105
Bremen 101
Jakarta 99
The Dalles 97
Marseille 96
Frankfurt am Main 89
Jinan 86
Tokyo 86
Rio de Janeiro 84
Abidjan 81
Toronto 79
San Mateo 74
Nuremberg 73
Warsaw 71
London 70
Phoenix 70
Atlanta 69
Montreal 64
Shenyang 64
Denver 63
Turku 63
Amsterdam 62
Brussels 62
Naples 61
Nanchang 60
Redmond 59
Tianjin 59
Guangzhou 58
Chennai 57
Kunming 56
Orem 55
Brooklyn 53
Hebei 53
Belo Horizonte 51
Houston 51
Modena 51
Fremont 50
Brno 49
Changsha 48
Baghdad 47
Biên Hòa 47
Hải Dương 46
Curitiba 44
Mexico City 44
Tashkent 44
Bengaluru 42
Poplar 42
Boston 41
Seoul 41
Stockholm 41
Pune 40
San Francisco 40
Verona 39
Dhaka 38
Norwalk 38
Quito 37
Brasília 34
Nairobi 34
Amman 33
Totale 29.131
Salva come PNG Salva come JPEG
Nome #
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 286
LINFOCITI INFILTRANTI IL TUMORE, BAP-1, VEGFR-2 E IGF-1R NEL MESOTELIOMA PLEURICO MALIGNO 269
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 255
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 255
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 251
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 248
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 221
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 221
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 216
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 216
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 214
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 213
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 212
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 210
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 210
227P Sexual dimorphism in immune profile of early and advanced NSCLC 207
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 207
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 206
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 205
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 203
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 200
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 200
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 197
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 197
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 196
Characterization of gefitinib uptake in NSCLC cell lines 195
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 193
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 190
Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. 190
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 189
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 188
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 187
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 186
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 186
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 181
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 181
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 181
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 180
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 180
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 178
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 178
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 178
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 177
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 177
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 176
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 176
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 175
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG CANCER (NSCLC 174
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 171
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 169
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 169
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 169
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 168
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 168
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 167
Neoplasie del polmone in Neoplasie del Distretto Toracico 167
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 165
Advantages of multidetector row CT with multiplanar reformation in guiding percutaneous lung biopsies. 165
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 165
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 165
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 164
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 162
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 162
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 162
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 161
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 161
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 160
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 160
IASLC and WHO 2004 Grading System as Prognostic Factors in 492 Cases of Pulmonary Adenocarcinoma 159
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 159
Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience 158
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 157
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 156
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 156
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 156
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 156
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 156
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 155
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 153
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 152
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) 152
Multiple primary malignancies involving lung cancer: a single-center experience 151
Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. 150
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 149
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 148
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 148
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 148
Semiautomatic analysis on computed tomography in locally advanced or metastatic non-small cell lung cancer: Reproducibility and Prognostic Significance of Unidimensional and 3-dimensional Measurements. 147
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 147
SMO mutations confer poor prognosis in malignant pleural mesothelioma 147
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 146
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 146
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. 146
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 146
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 145
Curved Needles in CT-Guided Fine Needle Biopsies of Abdominal and Retroperitoneal Small Lesions 145
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 145
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 145
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 145
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 144
Totale 17.824
Salva come PNG Salva come JPEG
Categoria #
all - tutte 190.413
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 190.413
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.778 0 32 60 101 51 34 304 136 82 41 134 803
2022/20236.278 806 675 367 428 518 681 70 410 1.991 28 219 85
2023/20242.925 134 199 90 89 288 652 209 199 127 195 256 487
2024/20259.002 220 570 662 514 913 879 452 376 1.079 913 757 1.667
2025/202623.405 1.715 1.799 2.944 2.197 3.262 1.210 2.371 829 2.880 1.737 1.530 931
2026/20272.178 910 1.268 0 0 0 0 0 0 0 0 0 0
Totale 49.969